| US 7,601,754 B2 | ||
| Flavonoid compounds as therapeutic antioxidants | ||
| Stuart Thomas Caldwell, Renfrewshire (United Kingdom); Christopher James Bennett, Dartford (United Kingdom); Richard Charles Hartley, Glasgow (United Kingdom); Donald Barton McPhail, Aberdeen (United Kingdom); and Garry Graeme Duthie, Aberdeen (United Kingdom) | ||
| Assigned to Antoxis Limited, Aberdeen (United Kingdom) | ||
| Appl. No. 10/521,232 PCT Filed Jul. 14, 2003, PCT No. PCT/GB03/03054 § 371(c)(1), (2), (4) Date Aug. 08, 2005, PCT Pub. No. WO2004/007475, PCT Pub. Date Jan. 22, 2004. |
||
| Claims priority of application No. 0216371.5 (GB), filed on Jul. 13, 2002. | ||
| Prior Publication US 2006/0137207 A1, Jun. 29, 2006 | ||
| Int. Cl. A61K 31/35 (2006.01); C07D 311/00 (2006.01) | ||
| U.S. Cl. 514—455 [514/453; 514/456; 549/400; 549/401; 549/403] | 34 Claims |
1. A compound of the following Formula 1:
 RA is a C2 to C30 saturated or unsaturated hydrocarbon chain;
R10, R11, R13, R14 and R3 each independently represent H, OH, a C1-6 ether, or a saturated or unsaturated hydrocarbon chain which may be substituted with one or more of nitro, halogen, amino,
hydroxyl, ketone or aldehyde group, and wherein at least one of R10, R11 and R13 represents OH;
optionally there is a double bond between C2 and C3 of the C ring;
n represents 0 or 1; and
RB is a C2 to C15 saturated or unsaturated hydrocarbon chain, and where RB is present, RA and RB are both C2 to C12 aliphatic alkyl chains.
|